- Trials with a EudraCT protocol (552)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
552 result(s) found for: Experimental drug.
Displaying page 1 of 28.
EudraCT Number: 2020-001435-27 | Sponsor Protocol Number: CHUBX2020/12 | Start Date*: 2020-04-10 |
Sponsor Name:CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC | ||
Full Title: Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety of several experimental treat... | ||
Medical condition: severe acute respiratory syndrome coronavirus 2(SARS-CoV 2) | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002072-26 | Sponsor Protocol Number: P150939 | Start Date*: 2016-08-25 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Multicenter randomized placebo controlled trial assessing the efficacy of oral adjuvant magnesium supplementation in the treatment of alcohol withdrawal syndrome. | |||||||||||||
Medical condition: Patients experiencing an alcohol withdrawal syndrome. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004660-47 | Sponsor Protocol Number: BCX1812-203 | Start Date*: 2007-11-20 |
Sponsor Name:BioCryst Pharmaceuticals Inc | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Virologic Activity, Safety, and Pharmacodynamics of Intravenous Peramivir for the Treatment of Experimental Influenza | ||
Medical condition: Treatment of experimental influenza | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002663-33 | Sponsor Protocol Number: NUH-ALS-2015-04 | Start Date*: 2018-11-05 | |||||||||||
Sponsor Name:Alloksys Life Sciences BV | |||||||||||||
Full Title: Preventing Oxidative stress induced Ischemic Injury and Systemic Inflammation complications during and after invasive Cardiac surgery with Alkaline Phosphatase (APPIRED III) | |||||||||||||
Medical condition: systemic inflammation as side-effect of heart-lung machine during cardiac surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) NL (Completed) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002392-10 | Sponsor Protocol Number: S59302 | Start Date*: 2017-02-02 |
Sponsor Name:UZ Leuven | ||
Full Title: Reconsolidation interference versus retrieval interference as the basis for experimental amnesia in humans – The effect of drug state at memory retrieval | ||
Medical condition: Experimental study with healthy participants recruited from the general population; no vulnerable individuals or clinical groups will be involved. Our objective is to test wether the internal drug ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002435-18 | Sponsor Protocol Number: Diclometh-2015 | Start Date*: 2015-07-27 | |||||||||||
Sponsor Name:Aalborg University Hospital | |||||||||||||
Full Title: An Evidence Based, Translational, Cross-Over, Randomized, Double-Blind, Placebo Controlled Study to Evaluate Effectiveness of Topically applied Combination of Diclofenac and Methadone Gel (Diclome... | |||||||||||||
Medical condition: Healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004542-15 | Sponsor Protocol Number: SGN22E-003 | Start Date*: 2020-08-03 | |||||||||||||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||||||||||||
Full Title: An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally a... | |||||||||||||||||||||||
Medical condition: Urothelial cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000805-26 | Sponsor Protocol Number: PSYKFORSK_MAT-MDD | Start Date*: 2021-11-19 |
Sponsor Name:Østfold Hospital Trust | ||
Full Title: An Open-Label, Phase 2, Feasibility Study of Manualized MDMA-Assisted Psychotherapy in Subjects with Major Depressive Disorder | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003736-22 | Sponsor Protocol Number: M17-142 | Start Date*: 2020-07-08 |
Sponsor Name:AbbVie Inc. | ||
Full Title: Bioavailability and Food Effect of Experimental Glecaprevir + Pibrentasvir Pediatric Formulation in Healthy Adult Subjects | ||
Medical condition: Hepatitis C virus (HCV) infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2013-000551-41 | Sponsor Protocol Number: IMPACT_Breast_6.3 | Start Date*: 2014-03-18 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion – Metastatic Breast Cancer | ||
Medical condition: Metastatic Breast Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000777-80 | Sponsor Protocol Number: SENS111-202 | Start Date*: 2018-06-08 |
Sponsor Name:Sensorion | ||
Full Title: A randomized, cross-over, placebo controlled, and meclizine calibrated study to assess the safety and pharmacodynamic effects of SENS-111 (100 mg and 200 mg) single dose in healthy subjects exposed... | ||
Medical condition: healthy volunteers (medicine for acute unilateral vertigo) | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003901-93 | Sponsor Protocol Number: RC2019.1.6_GIAQUINTO | Start Date*: 2020-05-27 | |||||||||||
Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA | |||||||||||||
Full Title: Monocentric, indipendent, phase II clinical trial, randomized in open to three different lZ delivery sequences in pediatric patients aged 1 and 12, in intensive care and mechanically ventilated. | |||||||||||||
Medical condition: Critical patients subjected to mechanical ventilation and hospitalized in PICU | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000788-95 | Sponsor Protocol Number: NSCLC1_INT | Start Date*: 2018-05-04 | ||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | ||||||||||||||||||
Full Title: Exploiting metformin plus/minus cyclic FAsting Mimicking diet (FMD) to improve the Efficacy of platinum-pemetrexed chemotherapy in advanced LKB1-mutated lung adenocarcinoma: the FAME trial | ||||||||||||||||||
Medical condition: Patients with LKB1-mutated advanced lung adenocarcinomas | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001718-13 | Sponsor Protocol Number: MP18 | Start Date*: 2019-10-18 |
Sponsor Name:MAPS Europe B.V. | ||
Full Title: An Open- Label, Phase 2, Multicenter Feasibility Study if Manualized MDMA-Assisted Psychotherapy with an fMRI sub-study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Dis... | ||
Medical condition: post-traumatic stress disorder (PTSD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) CZ (Completed) NO (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-000810-12 | Sponsor Protocol Number: CO41101 | Start Date*: 2019-12-09 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR META... | ||||||||||||||||||
Medical condition: Metastatic triple-negative breast cancer (TNBC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) FR (Completed) AT (Completed) PL (Completed) PT (Completed) IE (Prematurely Ended) ES (Completed) FI (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended) BG (Completed) DK (Completed) RO (Ongoing) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003024-16 | Sponsor Protocol Number: ACT16482 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Developpement | |||||||||||||
Full Title: Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM) - Master protocol | |||||||||||||
Medical condition: Plasma cell myeloma refractory | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) FR (Completed) GR (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001976-39 | Sponsor Protocol Number: CHDR1227 | Start Date*: 2013-07-30 |
Sponsor Name:Centre for Human Drug Research | ||
Full Title: Randomized, open-label, crossover study into the contribution of the intestines and kidney in the diurnal variation of Levofloxacin pharmacokinetics | ||
Medical condition: The circadian variation in the relative contribution of intestinal uptake and renal elimination of levofloxacin | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004761-28 | Sponsor Protocol Number: GEIS41 | Start Date*: 2019-06-20 |
Sponsor Name:Grupo Español de Investigación en Sarcomas | ||
Full Title: A multicenter, phase Ib/II trial of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) | ||
Medical condition: Gastrointestinal stromal tumor (GIST) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001626-22 | Sponsor Protocol Number: RML-TB | Start Date*: 2022-03-28 |
Sponsor Name:Vall d'Hebron Institute of Research | ||
Full Title: A Multicentre Controlled Open Randomized Clinical Trial to evaluate the efficacy and safety profile of an anti-TB drug combination based on High Dose Rifampicin, High Dose Moxifloxacin and Linezoli... | ||
Medical condition: Smear-positive rifampicin-sensitive pulmonary Tuberculosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000109-66 | Sponsor Protocol Number: TPU-TAS-102-301 | Start Date*: 2012-12-10 | |||||||||||
Sponsor Name:Taiho Oncology, Inc. | |||||||||||||
Full Title: RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO STANDARD CHEMOTHERAPIES | |||||||||||||
Medical condition: Refractory metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) SE (Completed) AT (Completed) ES (Completed) IE (Completed) CZ (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
